EQS-News: Biotest AG / Key word(s): Personnel Change in the Chief Financial Officer at Biotest AG 12.09.2024 / 15:00 CET/CEST The issuer is solely responsible for the content of this announcement. PRESS RELEASE
Change in the Chief Financial Officer at Biotest AG
Dreieich, Germany, September 12, 2024. The Supervisory Board of Biotest AG announced today that the former Chief Financial Officer, Ms. Ainhoa Mendizabal Zubiaga, is leaving the company for personal reasons. We would like to thank Ms. Mendizabal Zubiaga for her tireless efforts and dedication. The entire team wishes her every success and all the best for her future professional and personal endeavors. As part of this change, we welcome Mr. Martin Möller (52) as the new Interim Chief Financial Officer. Mr. Möller will assume this position for the next six months, effective September 14, 2024 and will be responsible for the The company would like to thank both individuals and looks forward with confidence to the next six months under Mr. Möller’s leadership. About Biotest Biotest is a provider of biological therapeutics derived from human plasma. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialized primarily in the areas of clinical immunology, hematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and hematopoietic systems. Biotest has more than 2,400 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange. Since May 2022, Biotest has been a part of the Grifols Group, based in Barcelona, Spain (www.grifols.com). IR contact Dr Monika Baumann (Buttkereit)
PR contact Dirk Neumüller Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com Ordinary shares: securities’ ID No. 522720; ISIN DE0005227201 Disclaimer 12.09.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group AG. The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
SSRIs and SNRIs Weaken Psilocybin’s Effects, New Study Finds
As psilocybin gains prominence in treating affective disorders like treatment-resistant depression and major depressive disorder, and advanced clinical trials aim to prove that the active